JP2023515055A5 - - Google Patents
Info
- Publication number
- JP2023515055A5 JP2023515055A5 JP2022549793A JP2022549793A JP2023515055A5 JP 2023515055 A5 JP2023515055 A5 JP 2023515055A5 JP 2022549793 A JP2022549793 A JP 2022549793A JP 2022549793 A JP2022549793 A JP 2022549793A JP 2023515055 A5 JP2023515055 A5 JP 2023515055A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- domain
- optionally
- cells
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979309P | 2020-02-20 | 2020-02-20 | |
| US62/979,309 | 2020-02-20 | ||
| US202063044597P | 2020-06-26 | 2020-06-26 | |
| US63/044,597 | 2020-06-26 | ||
| US202163136134P | 2021-01-11 | 2021-01-11 | |
| US63/136,134 | 2021-01-11 | ||
| PCT/US2021/018868 WO2021168317A1 (en) | 2020-02-20 | 2021-02-19 | Inhibitory chimeric receptor architectures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515055A JP2023515055A (ja) | 2023-04-12 |
| JP2023515055A5 true JP2023515055A5 (https=) | 2024-02-29 |
Family
ID=77391781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549793A Pending JP2023515055A (ja) | 2020-02-20 | 2021-02-19 | 阻害性キメラ受容体アーキテクチャ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230235051A1 (https=) |
| EP (1) | EP4107175A4 (https=) |
| JP (1) | JP2023515055A (https=) |
| CN (1) | CN115397845A (https=) |
| TW (1) | TW202144396A (https=) |
| WO (1) | WO2021168317A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022546315A (ja) * | 2019-08-20 | 2022-11-04 | センティ バイオサイエンシズ インコーポレイテッド | キメラ抑制性受容体 |
| AU2023314498A1 (en) * | 2022-07-26 | 2025-03-13 | Senti Biosciences, Inc. | Inhibitory chimeric receptor architectures |
| WO2024238769A2 (en) * | 2023-05-16 | 2024-11-21 | The Regents Of The University Of California | Inhibitory chimeric antigen receptors that reduce car-t cell "on-target, off-tumor" toxicity |
| WO2025096730A1 (en) * | 2023-11-01 | 2025-05-08 | University Of Virginia Patent Foundation | Novel autoregulated car t cells and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448035B1 (en) * | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US7265208B2 (en) * | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| IL311390A (en) * | 2013-03-15 | 2024-05-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| MX373687B (es) * | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| WO2016075612A1 (en) * | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| KR20180075689A (ko) * | 2015-11-23 | 2018-07-04 | 트르스티스 오브 보스톤 유니버시티 | 키메라 항원 수용체에 관한 방법 및 조성물 |
| EP4212166A1 (en) * | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
| BR112019006006A2 (pt) * | 2016-09-28 | 2019-06-25 | Gavish-Galilee Bio Applications Ltd. | molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico. |
| CN110582509A (zh) * | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| GB201707783D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| WO2019016784A1 (en) * | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | ANTI-NUCLEOLIN ANTIBODIES |
| WO2019068007A1 (en) * | 2017-09-28 | 2019-04-04 | Immpact-Bio Ltd. | UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) |
| US11866731B2 (en) * | 2017-11-10 | 2024-01-09 | Chineo Medical Technology Co., Ltd | Modified immune cells and uses thereof |
| BR112021006100A2 (pt) * | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| US20220170097A1 (en) * | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| JP2022546315A (ja) * | 2019-08-20 | 2022-11-04 | センティ バイオサイエンシズ インコーポレイテッド | キメラ抑制性受容体 |
| CN115052887B (zh) * | 2019-12-11 | 2026-03-31 | A2生物治疗公司 | 基于lilrb1的嵌合抗原受体 |
-
2021
- 2021-02-19 EP EP21756614.0A patent/EP4107175A4/en active Pending
- 2021-02-19 WO PCT/US2021/018868 patent/WO2021168317A1/en not_active Ceased
- 2021-02-19 TW TW110105857A patent/TW202144396A/zh unknown
- 2021-02-19 CN CN202180028773.9A patent/CN115397845A/zh active Pending
- 2021-02-19 JP JP2022549793A patent/JP2023515055A/ja active Pending
-
2022
- 2022-08-17 US US17/820,525 patent/US20230235051A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515055A5 (https=) | ||
| JP7305538B2 (ja) | 細胞によって発現される生物活性を調節する結合分子 | |
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2020530989A5 (https=) | ||
| JP2022002546A (ja) | 細胞 | |
| JP2022548778A5 (https=) | ||
| IL277398B1 (en) | Pd-l1 binding affimers, and uses related thereto | |
| EP3875484A1 (en) | Cll1-targeting antibody and application thereof | |
| JP2022512684A5 (https=) | ||
| JP2022530542A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2019525771A5 (https=) | ||
| CA3059444A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
| JP2018508215A5 (https=) | ||
| CA3030760A1 (en) | Humanized antibody against o-acetylated gd2 ganglioside (oacgd2) | |
| JP2017524367A5 (https=) | ||
| JP2021513857A5 (https=) | ||
| JP2022542559A5 (https=) | ||
| JP2024511423A5 (https=) | ||
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2023515471A5 (https=) | ||
| WO2020028572A2 (en) | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF | |
| US20230183342A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
| JP2024504162A5 (https=) | ||
| JP2022548112A5 (https=) |